StockViz
Share URL
Embed chart view
-
Export .csv
-
Download image
-
Copy link
-
Embed code
StockViz
RANKINGS
Novartis AG
Swiss Stock Exchange:NOVN.SW
Sector
Industries
Location
Market Cap
USD 244.72 B
Share Price
USD 123.90
Avg Daily Volume
4,098,771
Change (1 day)
0.34%
Change (1 year)
16.18%
Change (YTD)
26.33%
Novartis AG Research and Development (R&D) Expenses for the year ending December 31, 2024: USD 10.02 B
Novartis AG Research and Development (R&D) Expenses is USD 10.02 B for the year ending December 31, 2024, a -11.86% change year over year. Research and development (R&D) expenses are the costs associated with the development of new products, technologies, or improvements to existing products.
-
Novartis AG Research and Development (R&D) Expenses for the year ending December 31, 2023 was USD 11.37 B, a 13.76% change year over year.
-
Novartis AG Research and Development (R&D) Expenses for the year ending December 31, 2022 was USD 10.00 B, a 4.78% change year over year.
-
Novartis AG Research and Development (R&D) Expenses for the year ending December 31, 2021 was USD 9.54 B, a 6.24% change year over year.
-
Novartis AG Research and Development (R&D) Expenses for the year ending December 31, 2020 was USD 8.98 B, a -4.49% change year over year.
Competitors
AbbVie Inc.
USD 190.75
ABBV
+0.76
0.40%
Novo Nordisk A/S
USD 69.62
NOVO-B.CO
+0.45
0.65%
Roche Holding AG
USD 347.68
RO.SW
-0.20
-0.06%
Abbott Laboratories
USD 134.11
ABT
-2.15
-1.58%
AstraZeneca PLC
USD 141.63
AZN.L
-1.32
-0.93%
Merck & Co., Inc.
USD 82.39
MRK
+0.58
0.71%
Amgen Inc.
USD 296.85
AMGN
+6.33
2.18%
Pfizer Inc.
USD 25.32
PFE
+0.28
1.12%
Gilead Sciences, Inc.
USD 111.51
GILD
-0.22
-0.20%
Sanofi
USD 98.65
SAN.PA
+0.57
0.58%
Vertex Pharmaceuticals Incorporated
USD 457.03
VRTX
+4.87
1.08%
Bristol-Myers Squibb Company
USD 47.63
BMY
+0.12
0.25%
Chugai Pharmaceutical Co., Ltd.
USD 48.90
4519.T
-0.57
-1.16%
GSK plc
USD 19.21
GSK.L
-0.20
-1.02%
CSL Limited
USD 159.11
CSL.AX
+1.27
0.80%
Regeneron Pharmaceuticals, Inc.
USD 547.74
REGN
+12.83
2.40%
MERCK Kommanditgesellschaft auf Aktien
USD 132.97
MRK.DE
+0.27
0.20%
Jiangsu Hengrui Medicine Co., Ltd.
USD 7.29
600276.SS
-0.03
-0.39%
Takeda Pharmaceutical Company Limited
USD 30.65
4502.T
-0.23
-0.74%
Alnylam Pharmaceuticals, Inc.
USD 329.77
ALNY
+7.71
2.39%
Key Data
| Date | Research and Development (R&D) Expenses | Revenue | Revenue | Gross Profit |
|---|
Competitors
AbbVie Inc.
USD 190.75
ABBV
+0.76
0.40%
Novo Nordisk A/S
USD 69.62
NOVO-B.CO
+0.45
0.65%
Roche Holding AG
USD 347.68
RO.SW
-0.20
-0.06%
Abbott Laboratories
USD 134.11
ABT
-2.15
-1.58%
AstraZeneca PLC
USD 141.63
AZN.L
-1.32
-0.93%
Merck & Co., Inc.
USD 82.39
MRK
+0.58
0.71%
Amgen Inc.
USD 296.85
AMGN
+6.33
2.18%
Pfizer Inc.
USD 25.32
PFE
+0.28
1.12%
Gilead Sciences, Inc.
USD 111.51
GILD
-0.22
-0.20%
Sanofi
USD 98.65
SAN.PA
+0.57
0.58%
Vertex Pharmaceuticals Incorporated
USD 457.03
VRTX
+4.87
1.08%
Bristol-Myers Squibb Company
USD 47.63
BMY
+0.12
0.25%
Chugai Pharmaceutical Co., Ltd.
USD 48.90
4519.T
-0.57
-1.16%
GSK plc
USD 19.21
GSK.L
-0.20
-1.02%
CSL Limited
USD 159.11
CSL.AX
+1.27
0.80%
Regeneron Pharmaceuticals, Inc.
USD 547.74
REGN
+12.83
2.40%
MERCK Kommanditgesellschaft auf Aktien
USD 132.97
MRK.DE
+0.27
0.20%
Jiangsu Hengrui Medicine Co., Ltd.
USD 7.29
600276.SS
-0.03
-0.39%
Takeda Pharmaceutical Company Limited
USD 30.65
4502.T
-0.23
-0.74%
Alnylam Pharmaceuticals, Inc.
USD 329.77
ALNY
+7.71
2.39%